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Imaging-guided gene therapy of experimental gliomas
Abstract
To further develop gene therapy for patients with glioblastomas, an experimental gene therapy protocol
was established comprising a series of imaging parameters for (i) noninvasive assessment of viable
target tissue followed by (ii) targeted application of herpes simplex virus type 1 (HSV-1) amplicon
vectors and (iii) quantification of treatment effects by imaging. We show that viable target tissue
amenable for application of gene therapy vectors can be identified by multitracer positron emission
tomography (PET) using 2-18F-fluoro-2- deoxy-D-glucose, methyl-11C-L-methionine, or
3¶-deoxy-3¶-18Ffluoro- L-thymidine ([18F]FLT). Targeted application of HSV-1 amplicon vectors
containing two therapeutic genes with synergistic antitumor activity (Escherichia coli cytosine
deaminase, cd, and mutated HSV-1 thymidine kinase, tk39, fused to green fluorescent protein gene, gfp)
leads to an overall response rate of 68%, with 18% complete responses and 50% partial responses. Most
importantly, we show that the ‘‘tissue dose'' of HSV-1 amplicon vector-mediated gene expression can be
noninvasively assessed by -[4-18F-fluoro-3- (hydroxymethyl)butyl]guanine ([18F]FHBG) PET.
Therapeutic effects could be monitored by PET with significant differences in [18F]FLT accumulation
in all positive control tumors and 72% in vivo transduced tumors (P = 0.01) as early as 4 days after
prodrug therapy. For all stably and in vivo transduced tumors, cdIREStk39gfp gene expression as
measured by [18F]FHBG-PET correlated with therapeutic efficiency as measured by [18F]FLT-PET.
These data indicate that imagingguided vector application with determination of tissue dose of
vector-mediated gene expression and correlation to induced therapeutic effect using multimodal imaging
is feasible. This strategy will help in the development of safe and efficient gene therapy protocols for
clinical application.
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Abstract
 
Objective
 
Recombinant feline interferon omega (rFeIFN-
 
ω
 
), a type I IFN, may have 
the potential to limit virus replication and associated clinical signs when administered 
early on in the course of feline herpesvirus type 1 (FHV-1) infection and reactivation, 
respectively. The effect of rFeIFN-
 
ω
 
 pretreatment on the course of subsequent FHV-1 
infection in cats was investigated.
 
Animals studied
 
Nine SPF cats were divided into an IFN group (
 
n
 
 
 
=
 
 5) and a 
control-group (
 
n
 
 
 
=
 
 4).
 
Procedures
 
The IFN group was pretreated for 2 days with 10 000 units rFeIFN-
 
ω
 
 twice a 
day topically into both eyes and 20 000 units rFeIFN-
 
ω
 
 once a day orally, whereas the 
control group was mock-treated. Subsequently all cats were infected with FHV-1. 
Samples for FHV-1 DNA detection and quantitation, virus isolation, and titration of 
FHV-1 antibodies were collected. Clinical and ocular signs were recorded and scored.
 
Results
 
Courses of median individual clinical and ocular scores and virus load did not 
differ signiﬁcantly between both groups using 
 

 
 for repeated measurements. 
Analysis (
 

 
) of each individual ocular parameter revealed signiﬁcantly high scores for 
epithelial keratitis (
 
P
 
 
 
=
 
 0.016) in the IFN group compared to the control group. Periods 
of virus shedding did not differ signiﬁcantly between both groups using the Wilcoxon 
rank sum test.
 
Conclusions
 
Results indicated a lack of beneﬁcial effects of rFeIFN-
 
ω
 
 pretreatment in the 
course of primary FHV-1 infection in cats.
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INTRODUCTION
 
Feline herpesvirus-1 (FHV-1) is one of the most important
ocular and upper respiratory pathogens of domestic cats
worldwide. Clinical signs of acute infection include depres-
sion, fever, sneezing, serous nasal and/or ocular discharge,
conjunctivitis and epithelial keratitis.
 
1,2
 
Regular vaccination of FHV-1 in unexposed cats does not
prevent infection, viral shedding and establishment of a
FHV-1 carrier state when exposed to FHV-1.
 
3
 
 Furthermore,
primary FHV-1 infection may occur in unvaccinated weanl-
ings in close contact to a viral shedding dam.
 
4
 
 After produc-
tive infection in epithelial cells the virus develops neuronal
latency. During periodic reactivation FHV-1 is transported
back to surface sites where it may replicate.
 
2,5
 
 Innate and
adaptive immunity are important in modulating herpesvirus
infections of the epithelium and of the dorsal root ganglia.
 
6
 
It has been shown in mice diluted for IFN receptors that
type I IFNs play a major role in limiting replication of
herpes simplex type 1 (HSV-1), an alpha-herpesvirus-like
FHV-1, in the cornea and in the nervous system.
 
7
 
 Type I IFNs
(IFN-
 
α
 
/-
 
β
 
/-
 
ω
 
) are rapidly inducible components of the innate
immune response to infection.
 
8
 
 The potent activity of type I
IFNs against viral infections is mediated both by the immune
system and by intracellular antiviral pathways 
 
in vivo
 
.
 
9
 
 IFNs
do not act directly on the virus; rather, they trigger expres-
sion of various antiviral proteins and thus induce an antiviral
state within the host cell to limit replication and spread of
viruses.
 
10
 
 Furthermore, type I IFNs have been shown to
potently enhance innate and adaptive immune responses
 
in vivo
 
 through various immunomodulatory effects, such as
activation of dendritic cells (DCs), ampliﬁcation of antibody
responses
 
8
 
 and enhancement of T-cell and natural killer cell
cytotoxicity.
 
11
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In vitro
 
 studies using different cell types have shown antiviral
activities of type I IFNs against FHV-1.
 
12–15
 
In a preliminary study, cats experimentally infected with
FHV-1 and treated orally with 25 U of human IFN alpha
(HuIFN-
 
α
 
) once a day, beginning early on in the course of
infection, had less severe clinical signs than control cats.
 
16
 
As recombinant feline IFN omega (rFeIFN-
 
ω
 
) has greater
anti-FHV-1 effects than does rHuIFN-
 
α
 
2b 
 
in vitro
 
,
 
15
 
 it is of
interest to investigate anti-FHV-1 efﬁciency of rFeIFN-
 
ω
 
in vivo
 
. Antiviral activities of type I IFNs seem to be greater
when used before rather than after viral infection, both
 
in vitro
 
13,14
 
 and 
 
in vivo
 
.
 
17–19
 
Usually, primary FHV-1 infection occurs early in life
 
20
 
and, in the majority of cats presented to veterinarians with
signs of herpesvirus infection, virus reactivation has occurred
before possible IFN treatment could have been initiated.
However, because of a time lag of approximately 1 week
between exposure to stress or glucocorticoid administration
and reactivation of FHV-1 in carrier cats,
 
20
 
 treatment with
type I IFN prior to predicted periods of stress (pregnancy,
lactation, cat shows, animal shelters, change of residence) or
glucocorticoid administration may limit virus replication
and shedding following reactivation in FHV-1 latently
infected cats. Furthermore, type I IFNs are multifunctional
proteins not only inducing an antiviral state at the cellular
level but also enhancing the host’s immune response.
 
9
 
 Thus,
type I IFNs may have the potential to limit virus replication
during primary FHV-1 infection as well as during reactiva-
tion in FHV-1 carrier cats.
In a previous study we have shown dose-dependent
biologic activity of topically and orally applied rFeIFN-
 
ω
 
 on
conjunctival and white blood cells in cats.
 
21
 
 The present
study aimed to investigate effects of rFeIFN-
 
ω
 
 pretreatment
on the course of primary FHV-1 infection in cats.
 
MATERIALS AND METHODS
 
Animals
 
Nine (two spayed female and seven castrated male) 30-
month-old, speciﬁc pathogen-free (SPF) and FHV-1
seronegative cats (Harlan Sprague Dawley Inc., Madison,
WI, USA) were randomly allocated into two treatment
groups: ﬁve cats into the IFN group and four cats into the
control group. All cats were housed as a single group in
one large room. Experimental design was approved by the
veterinary ofﬁce of the canton Zürich, Switzerland
according to the Swiss Animal Protection Ordinance. Cats
had been used previously to investigate biologic activity of
rFeIFN-
 
ω
 
.
 
21
 
Interferon
 
Lyophilized rFeIFN-
 
ω
 
 (Virbagen
 
®
 
 Omega 5 
 

 
U, Virbac,
Switzerland) was mixed with 1 mL diluent (0.9% NaCl)
provided by the manufacturer and was further diluted with
9 mL of 0.9% NaCl solution to a ﬁnal concentration of
500 000 U/mL.
In vivo
 
 pretreatment protocol
 
Cats of the IFN group were pretreated with 1 drop (20 
 
µ
 
L,
measured by a micropipette) of 500 000 U/mL (10 000 U/
20 
 
µ
 
L) rFeIFN-
 
ω
 
 topically into the conjunctival sac of both
eyes twice a day as well as 2 drops of 500 000 U/mL
rFeIFN-
 
ω
 
 orally once a day for 48 h. Cats of the control
group were similarly mock-treated with the diluent alone
(0.9% NaCl solution).
 
Virus, cells and media
 
The FHV-1 ﬁeld isolate UT 88 was used for infection, which
has been proven previously to induce ocular and clinical
signs in SPF cats at a concentration of 10
 
7.1
 
 TCID
 
50
 
/mL.
 
22
 
Crandell feline kidney (CRFK) cells, grown in RPMI-medium
(RPMI 1640 L-Gluthamin, Gibco Invitrogen Corporation,
Grand Island, NY, USA) including 2.5% fetal calf serum,
100 U/mL penicillin, 0.1 mg/mL streptomycin and 0.5 mg/mL
gentamicin, were used to grow the virus stock and for virus
isolations and titrations, as described previously.
 
23
 
Virus inoculation
 
Sixteen hours after ﬁnal pretreatment all cats were infected
with FHV-1. For inoculation, 25 
 
µ
 
L of virus suspension
(10
 
7.1
 
 TCID
 
50
 
/mL) were dropped into the lower conjunctival
sac of each eye.
 
Clinical and ophthalmic examination
 
Prior to the study, all cats were examined clinically and ophthal-
mologically. Following virus inoculation, all cats were examined
daily for clinical symptoms (behavior, body temperature,
appetite, nasal discharge, sneezing and dyspnea) and every
other day for ocular signs (blepharospasm, epiphora, con-
junctival hyperemia, chemosis, epithelial keratitis, corneal
vascularization, and ﬂuorescein and rose Bengal staining).
The examiner (K.S.) was unaware of the assignment of the
cats to treatment groups. Clinical and ocular symptoms
were evaluated prior to sampling. Corneal parameters were
assessed using a portable hand-held binocular biomicro-
scope (KOWA SL-14, Kowa, Tokyo, Japan) and ﬂuorescein
(Fluoreszein, Haag Streit Int., Koniz, Switzerland) and rose
bengal dye (Minims™, Chauvin, Kingston-Upon-Thames,
UK). Fluorescein staining indicates epithelial defects. Rose
bengal staining indicates disruption of epithelial tight junc-
tions and tear ﬁlm abnormalities and is used in the diagnosis
of FHV-1 keratitis, as punctate and dendritic lesions may not
retain ﬂuorescein, but stain with rose bengal.
 
24
 
 Each ocular
sign was given a score on a scale of 0 (absent) to 3 (severe).
Clinical parameters were scored as ‘normal’ (0) or ‘abnormal’
(1). Body temperature (in 
 
°
 
C) was scored as follows: 38.0–
39.3 (0); 39.4–39.8 (1); 39.9–40.3 (2); 
 
≥
 
40.4 (3).
 
Sampling
 
Tear samples were obtained by placing a Schirmer tear
test (STT) strip (Schirmer-Tränen-Test, Essex Tierarznei,
München, Germany) into the nasal lower conjunctival sac of
each eye. The paper strip was cut off at the 5-mm mark and
 280
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stored in a sterile tube at –20 
 
°
 
C until further processing.
For virus isolation, lower conjunctival sacs of both eyes were
swabbed separately with sterile rayon tipped applicators
(Transwab
 
®
 
 ENT, Medical Wire & Equipment Co. Ltd.
Corsham, Wilts, UK). Swabs from both eyes were pooled in
a sterile tube containing 3 mL RPMI-medium and processed
immediately for virus isolation. Blood samples were taken
from the jugular vein to determine FHV-1 antibodies in a
serum neutralization test. Sixteen hours after ﬁnal pretreat-
ment and prior to experimental infection ocular and blood
samples from all cats were taken to ascertain FHV-1 free
status. Ocular samples were collected 24 h following FHV-1
infection and twice a week thereafter until FHV-1 DNA and
infectious virus were not detectable. Blood samples were
taken 2 and 10 weeks after virus inoculation to determine
FHV-1 antibody response.
 
Extraction of DNA
 
Extraction of DNA was performed using the DNeasy™
Tissue Kit (Qiagen AG, Hombrechtikon, Switzerland).
Each STT strip was processed separately. First, strips were
mixed with 22 
 
µ
 
L proteinase and 220 
 
µ
 
L ATL-buffer each,
vortexed for 15 s and incubated at 56 
 
°
 
C for 1 h. Following a
spin-down at 8000 
 
g
 
, 220 
 
µ
 
L AL-buffer was added and the
samples were incubated for 10 min at 70 
 
°
 
C. Following a
second spin-down at 8000 
 
g
 
, 220 
 
µ
 
L ethanol was added, mixed,
and vortexed for 15 s. The samples were then transferred to
a spin-column and processed according to the manufacturer’s
instruction. Extracted samples were kept at –20 
 
°
 
C until
analysis by TaqMan PCR.
 
Detection and quantitation of FHV-1
 
Detection and quantitation of FHV-1 DNA was performed
by Real-Time TaqMan PCR on an ABI PRISM 7700 sequence
detection system (Applied Biosystems, Rotkreuz, Switzer-
land) as described elsewhere.
 
25
 
 The ﬂuorescence threshold
cycle (Ct), at which ampliﬁcation of a PCR product is ﬁrst
detected, inversely correlates with the virus load, which is
calculated by the following formula: log TCID
 
50
 
 
 
=
 
 –0.2611
Ct 
 
+
 
 9.473.
 
25
 
 Ct-values 
 
≥
 
 45, corresponding to calculated virus
concentrations of 
 
≤
 
 10
 
–2.28
 
 TCID
 
50
 
, were considered negative.
 
Virus isolation
 
Cell culture methods and techniques of viral isolation have
been described previously.
 
23
 
 The cultures were examined
daily for 5 days for a cytopathic effect (CPE) indicative of
infectious virus. Supernatants of cultures negative for CPE
at this time were incubated a second time on CRFK cells and
examined for CPE for 5 days (blind passage).
 
Detection of FHV-1 antibodies
 
The constant virus-varying serum neutralization technique
according to Povey and Johnson was used.
 
26 Antibody titers
were expressed as the reciprocal of the highest serum dilu-
tion at which CPE was inhibited in 50% of inoculated
CRFK cell cultures.
Statistical analyzes
Results were presented as median and minimum (min), maxi-
mum (max). Disease (clinical and ocular) scores and Ct-values
were assigned as continuous variables and analyzed using
 for repeated measurements if proven to be sufﬁcient
normally distributed for parametric analysis. As analysis of
individual ocular parameters over the whole study period
resulted in co-linearity and because of different onset and
cessation of each individual ocular parameter, time frames of
reactive differences between IFN and control group were
extracted for analysis. Antibody titers, periods of virus
isolation and median individual total disease scores were
compared between both groups using Wilcoxon’s rank sum
test. Values of P < 0.05 were considered signiﬁcant and values
of ≥ 0.05 P ≤ 0.2 were stated as tendency. For statistical
analyzes the software StatView 5.1 (SAS Systems, Cary, NC,
USA) was used.
RESULTS
Clinical signs
Following infection with FHV-1 the course of clinical signs
was similar (P = 0.79) in all cats of both groups (Fig. 1). Clinical
signs started 2 days post infection (dpi) with reduced general
condition, reached a peak 7 dpi with all clinical signs, and
declined thereafter until cessation 2 weeks post infection in
both groups. The median (min/max) individual total clinical
score from 1 to 64 dpi was 26.0 (19/34) in the IFN group and
26.8 (22/33) in the control group and did not differ signiﬁ-
cantly between both groups (P = 0.73).
Ocular signs
Acute ocular signs (conjunctival hyperemia, chemosis, epi-
thelial keratitis, epiphora, blepharospasm) developed within
6 dpi in all animals (Fig. 2). Onset of corneal vascularization
was observed between 11 and 22 dpi in all animals. Peak of
Figure 1. Box plot course of clinical scores did not differ signiﬁcantly 
(P = 0.79 within time frame 5–12 dpi) between both groups: analysis 
over the whole study period resulted in colinearity; a time frame of 
reactive differences between both groups was extracted for analysis.
© 2007 American College of Veterinary Ophthalmologists, Veterinary Ophthalmology, 10, 278–284
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individual ocular scoring was reached on 8 dpi in both
groups (median [min/max] = 8 [6.5/9.5] IFN group vs. 7.8
[6/10] control group) and was mainly due to conjunctivitis
(hyperemia, chemosis), blepharospasm and epiphora. The
median (min/max) individual total ocular score from 1 to 64
dpi was 57 (44.5/78.5) in the IFN group and 51 (49.5/54.5)
in the control group and did not differ signiﬁcantly between
both groups (P = 0.32). Interaction of both groups for each
ocular parameter was analyzed separately to evaluate contri-
bution of each individual parameter to the course of ocular
scoring: There was no statistically signiﬁcant difference in
conjunctival hyperemia, chemosis, epiphora and neovascu-
larization between both groups throughout the observation
period. However, blepharospasm, epithelial keratitis (dendritic
and punctate lesions), and corneal staining properties were
signiﬁcantly different within deﬁned time frames when com-
paring both groups (Table 1).
Virus load
Samples of all cats taken immediately prior to FHV-1 infection
were FHV-1 DNA negative by TaqMan PCR. Statistical
analysis of the overall observation period (1–64 dpi) revealed
no signiﬁcant difference (P = 0.27) in the course of virus load
between both groups (Fig. 3). Within the time frame of
signiﬁcant difference in epithelial keratitis (11–35 dpi), there
was a weak tendency (P = 0.2) towards higher virus load in
the IFN group compared to the control group.
Virus shedding
No virus was isolated from samples of any cat taken immedi-
ately prior to FHV-1 infection. Post infection virus isolation
was successful from day 1 for a median of 25 (18/35) days in
IFN pretreated cats and for a median of 18 (18/29) days in
control cats. The period of virus shedding did not differ sig-
niﬁcantly between both groups (P = 0.27). Virus was isolated
Figure 2. Box plot course of ocular scores (all ocular parameters) 
did not differ signiﬁcantly (P = 0.11) between both groups within time 
frame 22–64 dpi: analysis over the whole study period resulted in 
co-linearity; a time frame of reactive differences between both groups 
was extracted for analysis.
Table 1. P-values, calculated for deﬁned time frames (dpi = day post infection), and median (min/max) total scores of ophthalmic parameters from 
1 to 64 dpi
Ophthalmic parameter P-value
Time frame
(dpi)
IFN-group median
(min/max) score
Control group median
(min/max) score
Epiphora 0.67 4–22 6 (5/8.5) 7.5 (4/15)
Blepharospasm 0.018* 1–64 4 (3/5.5) 5.8 (5/7)
Conjunctival hyperemia 0.66 1–18 12.5 (10/23.5) 12.8 (10/16.5)
Chemosis 0.14 4–13 2 (1/4) 3.8 (2.5/5.5)
Epithelial keratitis 0.016* 11–35 18.5 (14/24.5) 12.5 (8.5/17)
Neovascularization 0.75 15–43 3.5 (1.5/7.5) 5.3 (0.5/6)
Fluorescein staining 0.045* 11–25 3 (2/5) 1.8 (0/3)
Rose bengal staining 0.047* 11–29 7 (3/9) 3.8 (2/5)
*Signiﬁcant difference between both groups within given time frame. Note: time frames of reactive differences between both groups were extracted 
for analysis, as analysis over the whole study period resulted in co-linearity, and because of different onset and cessation of individual ocular 
parameters.
Figure 3. Box plot course of virus load (log TCID50), calculated 
from Ct-values by the following formula: log TCID50 = –0.2611 
Ct + 9.473.25 Course of virus load from 1 to 64 dpi did not differ 
signiﬁcantly (P = 0.27) between both groups.
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from swab samples from the conjunctival sac of all cats
whenever the Ct-value from the corresponding STT sample
of the same cat was 27.4 or less. Virus isolation from swabs was
not successful whenever the Ct-value of the corresponding
STT was 28.6 and higher.
FHV-1 antibodies
The development of serum neutralizing (SN) antibody titers
during the study is recorded in Fig. 4. Blood samples taken
prior to infection were negative for SN antibodies against
FHV-1 in all cats (data not shown). Comparing both groups,
SN antibody titers of IFN-pretreated cats were lower
(P = 0.76) at 2 weeks post infection, but were signiﬁcantly
higher (P = 0.016) at 10 weeks post infection than those of
control cats.
DISCUSSION
The importance of early initiation of IFN administration in
ocular herpesvirus infection has been described previously
in rabbits17,19 and monkeys,27 and has been demonstrated
in vitro.13,14 Early IFN administration is expected to induce
greater antiviral activity because of induction of an antiviral
state within the host cell prior to virus infection, and thus
more efﬁciently limiting infection, replication and spread of
virus than the induction of an antiviral state later in the
course of infection.
In the present study a rFeIFN-ω, approved for veterinary
use in Japan and European countries, was investigated for its
effectiveness to counteract primary FHV-1 infection in cats.
In a previous study we have shown dose-dependent biologic
activity of topically and orally applied rFeIFN-ω on con-
junctival and white blood cells in cats.21 Although type I
IFNs are known for their antiviral and immunomodulating
properties in numerous diseases,28,29 results of the present
study did not demonstrate any beneﬁcial effect of rFeIFN-ω
pretreatment in preventing or limiting FHV-1 infection and
associated clinical and ocular signs. Periods of virus shedding
were longer in IFN-pretreated cats than in control cats,
although differences were not statistically signiﬁcant. Simi-
larly, the course of virus load (FHV-1 DNA) did not differ
signiﬁcantly between both groups. The presence of FHV-1
DNA was demonstrated for longer periods than the prevalence
of infectious virus in ocular samples, and the correlation
between virus load and virus shedding was in agreement with
that in a previous study.25 Antibody titers of IFN-pretreated
cats were signiﬁcantly higher at 10 weeks post infection than
those of control cats, which may be explained by type I IFN’s
ability to enhance antibody response by direct stimulation
of B and T cells and via activation of DCs.30 There was no
signiﬁcant difference in the course and median individual
scores of clinical and overall ocular symptoms and virus load
between both groups. However, separate analysis of each
individual ocular parameter revealed signiﬁcantly higher
scores for epithelial keratitis and corneal staining properties
in the IFN group than in the control group.
In contrast to our results, in a preliminary study involving
20 FHV-1-positive cats, ocular signs improved signiﬁcantly
within 3 weeks following topical application of FeIFN-ω at
500 000 U/mL.31 However, in this multicenter clinical study
no control group was included to adjust for self-limiting
ocular signs. Also, a differentiation between acute epithelial
and chronic stromal keratitis, which is distinct in pathology
and pathogenesis, was not obvious. Epithelial keratitis is caused
by the cytolytic nature of herpes virus, leading to direct cellular
destruction and corneal ulceration and is usually seen in
primary infections, whereas stromal keratitis develops because
of immune mediation and inﬂammatory events as a result of
recurrence.2,32 Type I IFNs are able to induce both pro- and
anti-inﬂammatory effects, amongst others by modulating
IL-12 production, and thus govern the differentiation and
cytokine-secretion pattern of T cells.28,33 Whereas improve-
ment of stromal keratitis may be a result of anti-inﬂammatory
and immunomodulatory effects of type I IFNs on an immune-
mediated inﬂammatory condition, severity of epithelial
keratitis in the IFN group in the present study might have
been a result of different immunomodulatory effects of type
I IFN on the immune response to acute FHV-1 infection. As
the cytokine expression pattern has not been evaluated in the
present study, modulatory effects of type I IFN on FHV-1
infection and on cytokine expression pattern are unknown.
Because of the ambivalent nature of type I IFNs it is advisable
to use them with caution in ocular diseases.
In a previous experimental study by Cocker et al.,34 sub-
cutaneous application of massive doses (108 U/kg) of HuIFN-α
initialized prior to FHV-1 infection in cats did not reduce
virus titers and virus shedding, and the course of clinical
symptoms was delayed in IFN-treated compared to control
kittens. Amongst other reasons, the site of administration
may have resulted in low effectiveness, despite massive doses
of HuIFN-α. IFNs are cytokines from stimulated cells that
are produced locally to act locally, thus inducing an antiviral
state in surrounding cells.35 With respect to epitheliotropism
of FHV-1, parenteral application of FeIFN-ω at a distant
Figure 4. SN antibody titers of cats of the IFN (n = 5) and the control 
group (n = 4) 2 and 10 weeks post infection (wpi). *Statistically 
signiﬁcant difference between both groups.
© 2007 American College of Veterinary Ophthalmologists, Veterinary Ophthalmology, 10, 278–284
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site of viral replication may not be effective.35 FeIFN-ω
activity in conjunctival cells was seen after topical but not
after systemic administration in cats.21 Similarly, HuIFN
was effective in limiting herpetic keratitis in rabbits when
applied topically but not so when applied intramuscularly.36
Furthermore, it was shown in a preliminary experimental
study16 in cats that once-daily application of as little as 25 U
of HuIFN-α early on in the course of FHV-1 infection limited
clinical signs, although there was no effect on virus shedding.
Comparing results of this previous study with our present
results, it seems that HuIFN-α might be more efﬁcient at
least in limiting clinical signs following FHV-1 infection
compared to rFeIFN-ω.
Interestingly, type I IFNs possess some anti-FHV-1 activity
in vitro, with the rFeIFN-ω being more effective than rHuIFN-
α2b in CRFK cell cultures.15 In contrast, results of our study
and those of others16,34 have shown a lack of anti-FHV-1
activity of type I IFNs in vivo. As biologic activity of type I
IFNs in cats following topical and oral21 or subcutaneous37
administration has been demonstrated previously, lack of
anti-FHV-1 effects of type I IFNs in vivo appear to depend
on cellular sensitivity to IFN-mediated antiviral effects and
on relative resistance of FHV-1 to type I IFNs in vivo.
Indeed, various studies demonstrate that the magnitude of
antiviral effects strongly depends on type of target cell (host
cell), infecting virus and (sub)type of IFN used.12,38–40
Therefore, in vitro studies using cells other than cells natu-
rally infected by a speciﬁc virus are inappropriate to predict
antiviral effects of IFNs in vivo.
Moreover, viruses have developed evolutionary counter-
measures to facilitate productive infection and overcome host
immune responses.41 HSV-1, an alpha-herpesvirus inten-
sively investigated, is known to encode diverse functions to
inhibit the IFN response and thus to be able to combat the
IFN-mediated host defense, which has an important inﬂu-
ence on virus pathogenesis.42–45 Similar to antiviral effects of
IFN, virus countermeasures against the cellular IFN system
vary with cell type.46 In fact, efﬁcacy of type I IFNs has been
shown to vary with the species investigated. While topical
application of HuIFN-α in monkeys18 and rabbits17 is efﬁcient
in limiting herpes virus-induced keratitis, topical HuIFN-α
has inconsistent efﬁcacy in humans with herpetic keratitis
when used as a single treatment.47–49 With regard to the lack
of anti-FHV-1 effects of type I IFNs, we may speculate that
FHV-1, similar to HSV-1, possibly possesses anti-IFN stra-
tegies responsible for relative resistance of FHV-1 to type I
IFNs in cats.
In summary, considering the results of referenced studies,
efﬁcacy of exogenously applied IFN as a prophylactic or
therapeutic option depends on complex and speciﬁc
virus–host cell interactions. Many factors have an inﬂuence
on antiviral efﬁciency of IFNs, such as time-point of IFN
application in relation to virus infection, route of IFN
administration in relation to site of virus infection (sub)type
of IFN, IFN concentration, type of virus and host cell or
species investigated.
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